stonks4u
Sign up free
INTS logo

INTS Intensity Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$3.96
-0.04 (-1.00%)

Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those …

Market Cap: $10.70Mwww.intensitytherapeutics.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

120
120
Aug 11Aug 11

Quote

Day Range
$3.91 – $4.19
52-Week Range
$3.51 – $43.50
Volume
$39.1K
Market Cap
$10.70M
50-Day Avg
$4.24
200-Day Avg
$7.26
Prev Close
$4.00
Open
$3.91

Valuation & Ratios

P/E Ratio
-1.20
EPS
$-0.86
P/B Ratio
11.72
P/S Ratio
0.00
Debt/Equity
0.01
Current Ratio
5.92
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-97.7%
Return on Assets
-82.3%
FCF Yield
-6.6%
EV/EBITDA
-10.97

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-11.61M$-8.56
2024$0.00$-16.27M$-29.25
2023$0.00$-10.54M$-34.50
2022$0.00$-7.58M$-55.50
2021$0.00$-7.90M$-58.00

Social Signal Score

71
5d
71
2 mentions
—
30d
71
2 mentions
—
60d
71
2 mentions
—
90d
71
2 mentions
—
news: 2

Earnings

Thu, Nov 5(in 3 months)

Consensus estimate $-0.57 per share

3of 7 quarters beat consensus

Typical surprise -4.8% (median, so one quarter with a near-zero estimate can't distort it)

  • Tue, Aug 11$-1.11 vs $-0.87miss
  • Thu, May 7$-0.96 vs $-1.19beat
  • Fri, Mar 27$-1.69 vs $-1.24miss
  • Thu, Nov 6$-0.06 vs $-0.06beat
  • Thu, Aug 7$-0.13 vs $-0.06miss
  • Tue, May 13$-0.22 vs $-0.21miss

Estimates and results for INTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

INTShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (2)

  • Newsseekingalpha.com·4d ago·Positive

    Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsprnewswire.com·4d ago·Positive

    Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026 Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study Cash and cash equivalents of $9.5 million as of June 30, 2026 Increased business development activities Conference call begins at

    View source ↗